Back to search
Henoch-Schönlein Purpura Nephritis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Henoch-Schönlein Purpura Nephritis trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Henoch-Schönlein Purpura Nephritis trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy follow…
Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. About 40% of HSPN cases are accompanied by mild proteinur…
About 20% children with allergic purpura develop nephritis syndrome or nephrotic syndrome, 1% to 7% to kidney failure or end-stage renal disease. Children with…
This study is performed to evaluate the efficacy and safety of various measures in the treatment of HSPN in children.